The fourth batch of national centralized procurement for traditional Chinese medicine products concluded with a bid opening in Wuhan on April 30th, resulting in proposed winning selections. This procurement initiative included 89 drugs across 28 categories, with over 40,000 medical institutions reporting their needs. A total of 310 products from 243 companies were selected, indicating broad participation and the inclusion of commonly used clinical medications. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON This is a report on a government procurement process for traditional Chinese medicine, which is a policy-related event but not a major AI development.